GPCR
Price
$20.38
Change
+$0.03 (+0.15%)
Updated
Nov 4, 03:18 PM (EDT)
Capitalization
1.45B
One day until earnings call
Intraday BUY SELL Signals
WVE
Price
$3.62
Change
+$0.04 (+1.12%)
Updated
Nov 4, 04:59 PM (EDT)
Capitalization
705.43M
Intraday BUY SELL Signals
Interact to see
Advertisement

GPCR vs WVE

GPCR vs WVE Comparison Chart in %
View a ticker or compare two or three
VS
GPCR vs. WVE commentary
Nov 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GPCR is a Hold and WVE is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for GPCR with price predictions
Nov 03, 2026

GPCR's Indicator enters downward trend

The Aroon Indicator for GPCR entered a downward trend on November 03, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 162 similar instances where the Aroon Indicator formed such a pattern. In 144 of the 162 cases the stock moved lower. This puts the odds of a downward move at 89%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GPCR as a result. In 53 of 60 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GPCR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.

Bullish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

The Moving Average Convergence Divergence (MACD) for GPCR just turned positive on October 20, 2026. Looking at past instances where GPCR's MACD turned positive, the stock continued to rise in 30 of 37 cases over the following month. The odds of a continued upward trend are 81%.

Following a +8.54% 3-day Advance, the price is estimated to grow further. Considering data from situations where GPCR advanced for three days, in 177 of 209 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.

GPCR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 18 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.071) is normal, around the industry mean (3.051). P/E Ratio (-6.716) is within average values for comparable stocks, (-0.872). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (125.677) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.647).

The Tickeron Price Growth Rating for this company is 88 (best 1 - 100 worst), indicating slightly worse than average price growth. GPCR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GPCR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

A.I.Advisor
a Summary for WVE with price predictions
Nov 03, 2026

WVE's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for WVE turned positive on October 19, 2026. Looking at past instances where WVE's MACD turned positive, the stock continued to rise in 48 of 55 cases over the following month. The odds of a continued upward trend are 87%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where WVE's RSI Oscillator exited the oversold zone, 20 of 25 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.

The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on WVE as a result. In 63 of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.

Following a +13.40% 3-day Advance, the price is estimated to grow further. Considering data from situations where WVE advanced for three days, in 207 of 271 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 56 of 59 cases where WVE's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where WVE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.

WVE broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for WVE entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 29 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.555) is normal, around the industry mean (3.051). P/E Ratio (-3.315) is within average values for comparable stocks, (-0.872). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (125.677) among similar stocks. P/S Ratio (12.953) is also within normal values, averaging (439.647).

The Tickeron Seasonality Score of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 82 (best 1 - 100 worst), indicating slightly worse than average price growth. WVE’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. WVE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

FUNDAMENTALS RATINGS
WVE: Fundamental Ratings
WVE
OUTLOOK RATING
1..100
11
VALUATION
overvalued / fair valued / undervalued
1..100
29
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
98
PRICE GROWTH RATING
1..100
82
P/E GROWTH RATING
1..100
14
SEASONALITY SCORE
1..100
65

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
GPCRWVE
RSI
ODDS (%)
Bullish Trend 2 days ago
72%
Bullish Trend 2 days ago
80%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
79%
MACD
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
87%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
80%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
85%
Advances
ODDS (%)
Bullish Trend 16 days ago
85%
Bullish Trend 8 days ago
76%
Declines
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 3 days ago
86%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
86%
COMPARISON
Comparison
Nov 04, 2026
Stock price -- (GPCR: $20.35 vs. WVE: $3.58)
Brand notoriety: GPCR and WVE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GPCR: 50% vs. WVE: 74%
Market capitalization -- GPCR: $1.45B vs. WVE: $705.43M
GPCR [@Biotechnology] is valued at $1.45B. WVE’s [@Biotechnology] market capitalization is $705.43M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $134.53B. The average market capitalization across the [@Biotechnology] industry is $2.2B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GPCR’s FA Score shows that 2 FA rating(s) are green while WVE’s FA Score has 2 green FA rating(s).

  • GPCR’s FA Score: 2 green, 3 red.
  • WVE’s FA Score: 2 green, 3 red.
According to our system of comparison, both GPCR and WVE are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GPCR’s TA Score shows that 5 TA indicator(s) are bullish while WVE’s TA Score has 4 bullish TA indicator(s).

  • GPCR’s TA Score: 5 bullish, 3 bearish.
  • WVE’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, GPCR is a better buy in the short-term than WVE.

Price Growth

GPCR (@Biotechnology) experienced а -5.57% price change this week, while WVE (@Biotechnology) price change was +3.77% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.61%. For the same industry, the average monthly price growth was -11.21%, and the average quarterly price growth was -16.43%.

Reported Earning Dates

GPCR is expected to report earnings on Nov 05, 2026.

Industries' Descriptions

@Biotechnology (-3.61% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

GPCR and

Correlation & Price change

A.I.dvisor indicates that over the last year, GPCR has been loosely correlated with WVE. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if GPCR jumps, then WVE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GPCR
1D Price
Change %
GPCR100%
-0.59%
WVE - GPCR
64%
Loosely correlated
+1.70%
KYMR - GPCR
63%
Loosely correlated
-0.33%
NRIX - GPCR
49%
Loosely correlated
+0.47%
OCUL - GPCR
42%
Loosely correlated
+1.34%
OLMA - GPCR
39%
Loosely correlated
+3.96%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
MPU1.390.08
+6.11%
Mega Matrix Inc
CBAT1.100.06
+5.26%
CBAK Energy Technology Limited
MTZ198.104.33
+2.23%
MasTec
EVO1.550.03
+1.97%
Evotec SE
DAC153.14-0.82
-0.53%
Danaos Corp